Vimarsana
Biggest News Aggregation in the World

Page 3 - Gil Efron News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Gil Efron. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Gil Efron Today - Breaking & Trending Today

NT219 Plus Cetuximab Elicits Responses, Demonstrates Tolerability in Recurrent or Metastatic HNSCC - Vimarsana News

NT219 Plus Cetuximab Elicits Responses, Demonstrates Tolerability in Recurrent or Metastatic HNSCC

Second-line treatment with NT219 alone and in combination with cetuximab demonstrated safety and tolerability, and the combination produced confirmed partial responses in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.

Purple Biotech Reports Second Quarter 2023 Financial Results - Vimarsana News

Purple Biotech Reports Second Quarter 2023 Financial Results

Financial results represent clinical trials progress with recruitment at a pace faster than expected in CM24 Phase 2 studyClinical data from both studies expected in the coming months Cash runway...

Purple Biotech Reports Second Quarter 2023 Financial - Vimarsana News

Purple Biotech Reports Second Quarter 2023 Financial

Financial results represent clinical trials progress with recruitment at a pace faster than expected in CM24 Phase 2 studyClinical data from both studies...

Purple Biotech Reports Second Quarter 2023 Financial Results - Purple Biotech (NASDAQ:PPBT) - Vimarsana News

Purple Biotech Reports Second Quarter 2023 Financial Results - Purple Biotech (NASDAQ:PPBT)

Financial results represent clinical trials progress with recruitment at a pace faster than expected in CM24 Phase 2 studyClinical data from both studies expected in the coming months Cash runway extended into H1 2025

Purple Biotech : NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS - Form 6-K - Vimarsana News

Purple Biotech : NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS - Form 6-K

Bonuses 4.2.1. General Terms ... | May 1, 2023